Dyne Therapeutics expects cash to fund operations into Q3 of 2027

Dyne expects that its existing cash, cash equivalents and marketable securities, including the net proceeds from the July 2025 public offering and initial term loan tranche from Hercules Capital, will be sufficient to fund its operating expenses, debt service obligations, and capital expenditure requirements into the third quarter of 2027. Based on the company’s current plans and anticipated timelines, Dyne estimates that these funds would be sufficient to enable the company to: Obtain data from the registrational expansion cohorts of the ACHIEVE and DELIVER clinical trials; Submit BLAs to the FDA for DYNE-251 in DMD and DYNE-101 in DM1 using the Accelerated Approval pathway; and Commercially launch DYNE-251 in the U.S. if approved by the FDA.